Next Phase Newsletter

A venture capital firm based in Europe that focuses solely on the life sciences is investing from their third fund and is actively looking for new investments, usually in Series A & B rounds. Typically, the firm allocates €8M-€10M over the life of the investment with about half of that amount in the initial investment. The firm primarily invests in companies that are based in Europe, but will also consider opportunities in North America with more of a focus on the U.S.

The firm invests primarily in biotech therapeutics and medical devices. For biotech, the firm invests in pre-clinical up unto phase II assets. For medical devices, the firm prefers companies with initial clinical proof-of-concept up unto reaching regulatory approval, whether that be PMA or 510(k) approval. The firm is somewhat less interested in diagnostic technologies. The firm is generally agnostic in terms of subsectors and indications with the primary focus on products that address clear unmet opportunities. Historically, the firm has invested in biotech therapeutics that address a wide variety of inflammatory, orphan, respiratory, autoimmune, infectious and cardiovascular disorders. Medical device investments have included a non-active implantable device for pulmonary embolism, as well as devices for renal and cardiovascular and peripheral vascular diseases.

The firm requests a board seat in each portfolio company. The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A medical technology venture firm based in New England makes equity investments in early stage companies developing products for to accelerate the trend of precision medicine diagnostics. The firm seeks a leading investment position and deep involvement with its portfolio companies. Typical investment ranges from $5-15 M and is calibrated to milestone attainment. With a global view and global operational capabilities, the firm is currently seeking opportunities around the world.

The firm focuses on three market segments that support knowledge-generating precision medicine diagnosis: 1) mobile health, data analytics, and healthcare IT; 2) high specificity in-vivo and in-vitro diagnostics; and 3) diagnostic technologies that guide or are a companion to precision therapies. The firm is looking for technologies that will dramatically improve patient health and have the potential for global markets and scale.

The firm is looking for experienced management teams with deep domain expertise. The firm typically request board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A pharma firm headquartered in Tokyo, Japan focuses on two main sectors: pharmaceutical and medical device for home healthcare. The company is seeking innovative medical technologies to strengthen its pipeline while expanding into new areas. The company is looking for in-licensing and collaborative R&D opportunities in the US, Canada, EU, and Israel.

The firm has existing businesses in respiratory diseases, cardiovascular disease, and orthopedics. The firm is seeking innovative, home-care, therapeutic medical devices in the disease sectors described above. The firm is also interested in home patient monitoring products. In addition, the firm is looking for innovations in the following areas: neurological disorders such as stroke, depression, Parkinson’s disease, etc.; cancer; wound care; and rehabilitation, which are all must be used at home care. The company is most interested in PMA and de novo therapeutic devices in the home-care settings. The company prefers assets with initial patient data. Furthermore, the firm is seeking opportunities in digital medicine business (but not for consumer products) in disease areas described above.

Within pharmaceuticals, the firm is looking for late clinical stage assets in orthopedics, respiratory diseases, and cardiovascular diseases. The firm is most interested in small molecule and peptide drugs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private equity firm based in Philadelphia, PA provides expansion and growth capital to commercial-stage companies in select healthcare sectors. The firm recently closed its first fund in June of 2016 at $200M, and is targeting initial equity investments around $10M with up to another $5M-$10M in additional capital reserved for follow-on investments. The partners of the firm have significant experience investing in and building healthcare companies, and look to leverage their operational experience to help portfolio companies grow and scale. The firm is focused on US-based companies, and prefers to lead rounds but will also participate as a minority investor in a syndicate. The firm is targeting 3-4 investments per year.

The firm is focused on commercial-stage companies within specialty pharmaceutical, medical technology, healthcare services and digital health that are generating at least $5M in revenue. It is not a requirement that the company have positive EBITDA, but should be anticipating positive cash flow within 18 months. 1315 Capital has particular interest in obesity prevention, opioid addiction, podiatry and cosmeceuticals.

The firm prefers to work with experienced management teams and typically avoids first time entrepreneurs, but will evaluate companies with a great product and complete management team. The firm prefers to work with companies that have more than one product. The firm does seek a board seat along with investment and prefers to be involved with the management team, given the firm’s expertise in operations and ability to directly help the company scale.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital arm of a global science-based company active in health, nutrition and materials makes equity investments into seed and venture stage companies, generally taking less than 25% ownership. The firm makes allocations ranging from a few hundred thousand dollars to $5 million initially with additional capital held for future financing rounds. The firm is looking make approximately 5-10 investments over the next 6-9 months with +10 being made over the next 2 years. The firm invests in companies located around the globe with a focus on the U.S., Europe and Isreal.

The firm is looking for materials science companies in orthopedics, soft tissue repair and drug delivery. The firm also actively invests in human nutritional health and advanced materials for solar energy . While the firm has invested in companies all the way from seed to PIPE, they generally invest into companies that have products in development or early stage commercialization.

The firm highly values experience in a firms management team and generally looks to take a board seat and play an active role in its portfolio companies. The firm is looking for companies that are interested in cooperation/alignment with the parent company’s relevant businesses.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A pharmaceutical enterprise headquartered in Beijing, China has set up a biotech subsidiary in the USA and is actively seeking cutting-edge life science technologies around the world. The firm makes equity investments of US$2-10 million in Seed to Series B stage companies, while later stages up to pre-IPO may also be considered. For overseas deals, the firm prefers to co-invest with top-tier lead investors. The firm is looking for opportunities across the globe.

The firm is looking for technologies that are a strategic fit with its portfolio across biopharmaceuticals, medical devices, healthcare IT and healthcare services. The firm is most interested in innovative platform technology in small molecule or biologic therapeutics targeting large markets in China, including aging population, oncology, diabetes, women and children’s health. The firm considers early-stage companies from seed to Series B.

The firm seeks experienced management teams backed by strong, reputable VC firms. The firm typically requests board representation post-investment. The firm prefers to retain China rights, but this is not a requirement for investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global diagnostics firm headquartered in Europe is conducting global business development and licensing searches in all stages of clinical diagnostics research and development, regardless of the technology involved. The firm employs a variety of deal structures including IP rights in- and out- licensing, product or technology co-development,  and M&A.

The firm is interested in new technologies in point of care diagnostics, molecular diagnostics, tissue diagnostics, bioinformatics, and instrumentation, sequencing and associated software. The firm’s indications of interest include oncology, sepsis, pre-natal health and women’s health, bone metabolism, cardiovascular disease, diabetes and metabolic disease, kidney disease, infectious disease, and genetic disorders.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com